Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of the Pharmacokinetics and Safety of Venetoclax in Subjects With Impaired Renal Function

Next Previous
Trial Profile

Evaluation of the Pharmacokinetics and Safety of Venetoclax in Subjects With Impaired Renal Function

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 09 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Venetoclax (Primary)
  • Indications Acute myeloid leukaemia; Blastic plasmacytoid dendritic cell neoplasm; Breast cancer; Cancer; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Multiple myeloma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Precursor cell lymphoblastic leukaemia-lymphoma; Prostate cancer; Small cell lung cancer; T-cell prolymphocytic leukaemia; Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors AbbVie

Most Recent Events

  • 06 Jun 2023 Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
  • 15 Sep 2022 Status changed from active, no longer recruiting to completed.
  • 18 Jul 2022 Planned End Date changed from 26 May 2022 to 29 Jul 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top